Christopher Dimitri

Christopher Dimitri

Company: GSK

Job title: Investigator


Christopher joined GSK in 2016 and with others developed the Encoded Library Technology platform to serve as a robust technology with which to assess small molecule tractability of novel targets.  Prior to joining GSK, he worked with aptamers as both research tools while at Novartis and as a therapeutic modality while at Archemix. He obtained my Ph.D. in Cell Biology from Harvard Medical School where worked on the Ras-MAPK signaling pathway in the lab of Dr. John Blenis.


Predicting Small Molecule Tractability of Novel Targets to Prioritize and Accelerate Hit Identification Activities 1:30 pm

Advances in both genome-wide screening and genome-wide analyses have enabled the identification of numerous putative therapeutically relevant targets for hit identification programs. Pursuing all of these targets in small molecule hit ID programs is neither feasible nor warranted Integrating both in silico and experimental methods to rapidly predict the small molecule tractability of novel targets…Read more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.